Cargando…

A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects

Objective: To evaluate the tolerance, variability, and pharmacokinetics (PK) of QX001S, a biosimilar for ustekinumab, in healthy Chinese men. Methods: One hundred and seventy-eight healthy men were recruited in this randomized, double-blind, single-dose, two-arm, parallel study, and received 45 mg o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Lei, Li, Qingmei, Zhang, Hong, Wu, Min, Fang, Min, Yang, Lizhi, Li, Xiaojiao, Liu, Jingrui, Li, Cuiyun, Chen, Hong, Zhu, Xiaoxue, Ding, Yanhua, Zhou, Mingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167066/ https://www.ncbi.nlm.nih.gov/pubmed/34084144 http://dx.doi.org/10.3389/fphar.2021.675358

Ejemplares similares

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra(®)) in Chinese healthy subjects
por: Zhang, Hong, et al.
Publicado: (2021)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
por: Zhang, Hong, et al.
Publicado: (2021)

Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects
por: Zhang, Hong, et al.
Publicado: (2018)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects
por: Zhang, Hong, et al.
Publicado: (2020)

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
por: Zhang, Hong, et al.
Publicado: (2021)

Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese Subjects
por: Li, Xiaojiao, et al.
Publicado: (2021)

First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects
por: Zhang, Hong, et al.
Publicado: (2022)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
por: Li, Qingmei, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers
por: Wu, Min, et al.
Publicado: (2022)

Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial
por: Wu, Min, et al.
Publicado: (2022)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
por: Zhang, Hong, et al.
Publicado: (2021)

Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors
por: Liu, Jingrui, et al.
Publicado: (2021)

First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults
por: Liu, Jingrui, et al.
Publicado: (2021)

A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza(®)) in Healthy Male Subjects
por: Mai, Gang, et al.
Publicado: (2021)

A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta(®) in healthy male subjects
por: Sun, Yuanyuan, et al.
Publicado: (2022)

A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects
por: Huang, Kai, et al.
Publicado: (2021)

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA(®) in Chinese healthy male subjects
por: Cao, Guoying, et al.
Publicado: (2023)

Safety, Pharmacokinetics, and Pharmacodynamics of a Single Bolus of the γ-aminobutyric Acid (GABA) Receptor Potentiator HSK3486 in Healthy Chinese Elderly and Non-elderly
por: Li, Xiaojiao, et al.
Publicado: (2021)

Comparison of pharmacokinetics and safety between CE-fosphenytoin sodium, fosphenytoin sodium, and phenytoin sodium after intravenous and intramuscular administration in healthy volunteers
por: Li, Xiaojiao, et al.
Publicado: (2023)

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection
por: Zhang, Hong, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
por: Chen, Hanjing, et al.
Publicado: (2022)

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers
por: Liu, Jingrui, et al.
Publicado: (2020)

Comparative genomics of QX-like infectious bronchitis viruses in Korea
por: Hong, Seung-Min, et al.
Publicado: (2017)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
por: Huang, Hui-Yao, et al.
Publicado: (2020)

Population Pharmacokinetic Model of AST-001, L-Isomer of Serine, Combining Endogenous Production and Exogenous Administration in Healthy Subjects
por: Lee, Soyoung, et al.
Publicado: (2022)

Read by QxMD
por: Klatt, Carolyn A.
Publicado: (2020)

Effect of 0.01% Atropine on Accommodation in Myopic Teenagers
por: Li, Huixia, et al.
Publicado: (2022)

Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product
por: Cantin, Greg, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus(®) in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
por: Wang, Yiya, et al.
Publicado: (2022)

The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats
por: Zhang, YuJun, et al.
Publicado: (2019)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
por: Li, Xiaojiao, et al.
Publicado: (2018)

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment
por: Hu, Yue, et al.
Publicado: (2022)

Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study
por: Yao, Lingya, et al.
Publicado: (2021)

Non-clinical development of CER-001
por: Barbaras, Ronald
Publicado: (2015)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
por: Colloca, Luana, et al.
Publicado: (2019)

Editorial: Biological drugs and biosimilars in autoimmune diseases
por: Wajda, Anna, et al.
Publicado: (2023)

Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach
por: Yang, Jianhong, et al.
Publicado: (2022)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ph1mm1k4mgq6oier9u5sh1k0m1